Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614.

View in: PubMed

subject areas

Adenocarcinoma
Androgen Antagonists
Benzamides
Combined Modality Therapy
Gonadotropin-Releasing Hormone
Humans
Male
Neoplasm Metastasis
Nitriles
Patient Reported Outcome Measures
Phenylthiohydantoin
Prostatic Neoplasms, Castration-Resistant
Quality of Life
Time Factors

authors with profiles

Russell Z. Szmulewitz